CAMBRIDGE, UK and NEW YORK, USA, 7 April March 2021: Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generation DDR targets to enhance Novartis’s Radioligand Therapies (RLT).
Under the three-year collaboration, Artios and Novartis will perform target discovery and validation, and Novartis will select up to three exclusive DDR targets, and receive worldwide…
Cambridge, UK, 06 April 2021: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced that it has secured £2.7m in new equity financing, including £2.25m from lead investor Gresham House Ventures. The funding will be used to expand Metrion’s laboratories in Cambridge, UK, invest in specialist equipment, develop its cell line library, and add GLP cardiac safety services. The financing will also enable the expansion of the Company’s business development activities.
Metrion Biosciences’ ion channel expertise includes an industry leading…
As the UK and Japan embark on a new trade deal, there are aspirations of greater collaboration and investment between the two nations. Dr. Jorg Taubel shares his thoughts on the future needs of the Japanese pharmaceutical market and how UK-Japanese scientific relations can support this in his recent article in Pharmaceutical Market Europe and PMLive.
Dr. Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad –…
Evotec is excited to be launching its new Science Pool- a content hub for scientific knowledge and resources including articles and whitepapers, videos and webinars, posters, guides, case studies and more!
The resources on the Science Pool feature exciting new research, insights into regulatory news and trends in the industry - enabling users to keep ahead of the game with respect to new developments in their respective fields. Opinions and reviews on current areas of science are shared on the Evotec blog with many of the articles focusing on new groundbreaking research.
So why not expand…
Coveted award for Phase II clinical development of lead product, AT247, its next generation ultra-rapid acting Insulin
Cambridge, UK., 31st Mar 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Innovate UK to support the Phase II development of AT247, its ultra-rapid acting insulin product candidate which is based on Arecor’s proprietary Arestat™ technology platform.
Sarah Howell, Chief Executive Officer of Arecor, said: " We are proud…
Cambridge, UK: 31 March 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes facilitating connections between companies and with investors. Cambridge Innovation Capital (CIC), the renowned investor backing and building world-leading deeptech and life sciences companies in the Cambridge ecosystem, has become the latest company to join the One Nucleus Partner Programme. The programme is tailor-made to…
CAMBRIDGE, UK 30 March 2021 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the appointment of Michael Daniels, PhD, as Head of Product Management. In this role, Dr Daniels will be focused on the development and introduction of Evonetix’s first product, a DNA desktop writer. He will work closely with the prospective customers and users of the Company’s products as well as the team’s engineers and research scientists.
Dr Daniels brings with him over 15 years’ experience of…
Turnover at leading pharmaceutical and biotech product development consultancy Boyds has surged by a record-breaking 25 percent as demand for its specialist services continues to grow.
The company, which was established 16 years ago by Professor Alan Boyd and supports the development of medicines for patient benefit, has already added seven regulatory and medical affairs experts to its team, and is now launching an even larger recruitment drive creating up to ten new roles to enhance its expertise, service demand for its services, and expand the business.
Boyds has partnered with UK…
AMSBIO, in association with Nordmark Biochemicals, is now offering animal-free Collagenase and Neutral Protease enzymes, isolated from Clostridium histolyticum, for in vitro tissue dissociation leading to high yields of viable cells.Being animal-free, these enzymes are very safe and offer reduced regulatory hurdles for use in clinical applications. They are manufactured under GMP guidelines using a plant-based production process that guarantees no risk of cross-contamination with animal-derived materials. These top-quality enzymes can be used on a wide range of cell/tissue types and…
From mobile apps to digital biomarkers, transformative technologies – such as
artificial intelligence, machine learning and virtual reality – are enabling the creation of unique and novel digital health innovations, ultimately changing our definition of what a medical device is. By crossing the line from tracking, to diagnosis and treatment using tools like AI symptom checkers, a product is no longer classified as a wellness consumer product, but instead it becomes a medical device. Spanning from sample detection and diagnosis to the treatment of mental health disorders, the opportunities are…